IL92471A - A pharmaceutical preparation containing an antagonist for the action of a platelet agent - Google Patents

A pharmaceutical preparation containing an antagonist for the action of a platelet agent

Info

Publication number
IL92471A
IL92471A IL9247189A IL9247189A IL92471A IL 92471 A IL92471 A IL 92471A IL 9247189 A IL9247189 A IL 9247189A IL 9247189 A IL9247189 A IL 9247189A IL 92471 A IL92471 A IL 92471A
Authority
IL
Israel
Prior art keywords
compounds
endotoxin
antagonist
phenyl
paf
Prior art date
Application number
IL9247189A
Other languages
English (en)
Hebrew (he)
Other versions
IL92471A0 (en
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of IL92471A0 publication Critical patent/IL92471A0/xx
Publication of IL92471A publication Critical patent/IL92471A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Thermistors And Varistors (AREA)
  • Measurement Of Force In General (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Surgical Instruments (AREA)
  • Percussive Tools And Related Accessories (AREA)
  • Disintegrating Or Milling (AREA)
IL9247189A 1988-12-19 1989-11-27 A pharmaceutical preparation containing an antagonist for the action of a platelet agent IL92471A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28620188A 1988-12-19 1988-12-19

Publications (2)

Publication Number Publication Date
IL92471A0 IL92471A0 (en) 1990-08-31
IL92471A true IL92471A (en) 1995-06-29

Family

ID=23097534

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9247189A IL92471A (en) 1988-12-19 1989-11-27 A pharmaceutical preparation containing an antagonist for the action of a platelet agent

Country Status (18)

Country Link
US (1) US5124147A (fi)
EP (1) EP0374510B1 (fi)
JP (1) JP2931344B2 (fi)
KR (1) KR0148680B1 (fi)
AT (1) ATE147634T1 (fi)
AU (1) AU624457B2 (fi)
CA (1) CA2005670A1 (fi)
DE (1) DE68927671T2 (fi)
DK (1) DK641889A (fi)
ES (1) ES2096553T3 (fi)
FI (1) FI896046A0 (fi)
GR (1) GR3022969T3 (fi)
IL (1) IL92471A (fi)
NZ (1) NZ231725A (fi)
PH (1) PH31376A (fi)
PT (1) PT92596B (fi)
SG (1) SG43205A1 (fi)
ZA (1) ZA899685B (fi)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5147864A (en) * 1988-12-19 1992-09-15 American Cyanamid Company Bis-arylphosphate ester antagonists of platelet activating factor
US5231091A (en) * 1988-12-19 1993-07-27 American Cyanamid Company Bis-arylphosphate ester antagonists of platelet activating factor
US4983592A (en) * 1988-12-19 1991-01-08 American Cyanamid Co. Bis-arylphosphate ester antagonists of platelet activating factor
GB8918232D0 (en) * 1989-08-10 1989-09-20 Opal Stephen M Pharmaceutical product for the treatment of septic shock
US6315999B1 (en) 1989-08-10 2001-11-13 Solvay, S.A. Pharmaceutical product for the treatment of sepsis
US5843693A (en) * 1989-08-16 1998-12-01 Chiron Corporation Assay method for screening for inhibitors of proTNF conversion
US6586222B1 (en) 1989-08-16 2003-07-01 Chiron Corporation Recombinant PR-3 and compositions thereof
US5998378A (en) * 1989-08-16 1999-12-07 Chiron Corporation Compositions for the inhibition of TNF hormone formation and uses thereof
AU3244693A (en) * 1991-12-17 1993-07-19 Schering Corporation Use of the combination of anti-tumor necrosis factor plus interleukin-6 to treat septic shock
US6193969B1 (en) 1993-06-03 2001-02-27 Protherics Inc. Antibody fragments in therapy
IL110787A0 (en) * 1993-08-27 1994-11-11 Sandoz Ag Biodegradable polymer, its preparation and pharmaceutical composition containing it
CA2179383A1 (en) * 1994-01-14 1995-07-20 Ira D. Goldfine Antagonists to insulin receptor tyrosine kinase inhibitor
CA2185162A1 (en) 1994-03-07 1995-09-14 Robert F. Halenback (Deceased) Compositions for the inhibition of tnf formation and uses thereof
US5939269A (en) * 1994-12-28 1999-08-17 The Regents Of The University Of California Antagonists to insulin receptor tyrosine kinase inhibitor
JP4231106B2 (ja) * 1995-01-23 2009-02-25 ゼノテック インコーポレイティッド 骨溶解および転移を改善する方法
US20020025316A1 (en) * 1995-08-18 2002-02-28 Ferguson Mark Williams James Pharmaceutical composition containing inhibitors of interferon-gamma
GB2304342A (en) * 1995-08-18 1997-03-19 Univ Manchester Pharmaceutical comprising either an inhibitor or a stimulator of interferon gamma
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US20020199218A1 (en) * 1999-08-19 2002-12-26 Daphne Goring Proline-rich extensin-like receptor kinases
CA2364983A1 (en) * 2000-12-13 2002-06-13 John R. Coleman Nucleic acid molecules and polypeptides for catabolism of abscisic acid
US7556807B2 (en) 2001-02-20 2009-07-07 Kane Biotech, Inc. Signal peptides, nucleic acid molecules and methods for treatment of caries
US7597895B2 (en) * 2001-02-20 2009-10-06 The Governing Council Of The University Of Toronto Signal peptides, nucleic acid molecules and methods for treatment of caries
CA2868614A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
TWI556829B (zh) 2004-04-09 2016-11-11 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
WO2006081139A2 (en) 2005-01-26 2006-08-03 Abgenix, Inc. Antibodies against interleukin-1 beta
TWI399384B (zh) 2005-05-16 2013-06-21 Abbott Biotech Ltd ＴＮＦα抑制劑於治療侵蝕型多發性關節炎之用途
WO2007117490A2 (en) 2006-04-05 2007-10-18 Abbott Biotechnology Ltd. Antibody purification
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
CA2766272C (en) 2009-06-26 2021-02-09 Soricimed Biopharma Inc. Soricidin derived peptides and methods for the detection of trpv-6 cancers and drug delivery
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
CA2905010A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2016160976A2 (en) 2015-03-30 2016-10-06 Abbvie Inc. Monovalent tnf binding proteins
EP3078675A1 (en) 2015-04-10 2016-10-12 Ares Trading S.A. Induction dosing regimen for the treatment of tnf alpha mediated disorders
JOP20190162A1 (ar) 2016-12-30 2019-06-27 Biocad Joint Stock Co تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148879A (en) * 1977-12-23 1979-04-10 Nelson Research & Development Company Inhibition of platelet aggregation with selected phosphonic and phosphinic acid esters

Also Published As

Publication number Publication date
IL92471A0 (en) 1990-08-31
ZA899685B (en) 1990-09-26
JP2931344B2 (ja) 1999-08-09
GR3022969T3 (en) 1997-06-30
JPH02212435A (ja) 1990-08-23
DK641889D0 (da) 1989-12-18
KR0148680B1 (ko) 1998-08-17
DK641889A (da) 1990-06-20
ATE147634T1 (de) 1997-02-15
PT92596B (pt) 1996-06-28
US5124147A (en) 1992-06-23
DE68927671T2 (de) 1997-05-07
NZ231725A (en) 1992-12-23
AU4688589A (en) 1990-06-21
PH31376A (en) 1998-10-29
DE68927671D1 (de) 1997-02-27
EP0374510B1 (en) 1997-01-15
AU624457B2 (en) 1992-06-11
FI896046A0 (fi) 1989-12-18
CA2005670A1 (en) 1990-06-19
KR900009097A (ko) 1990-07-02
SG43205A1 (en) 1997-10-17
EP0374510A1 (en) 1990-06-27
ES2096553T3 (es) 1997-03-16
PT92596A (pt) 1990-06-29

Similar Documents

Publication Publication Date Title
IL92471A (en) A pharmaceutical preparation containing an antagonist for the action of a platelet agent
KR100770695B1 (ko) 말초 카나비노이드 수용체 특이적 아고니스트
US4528195A (en) Imidazole derivatives and salts thereof, their synthesis and intermediates and pharmaceutical formulations
Nudelman et al. Novel anticancer prodrugs of butyric acid. 2
JPH0154339B2 (fi)
CA2153686A1 (en) Angiogenesis inhibitor and novel compound
IL228630A (en) Compounds for the treatment of metabolic syndrome and intermediates for the synthesis of these compounds
JPS6366153A (ja) バルプロ酸または（ｅ）―２―バルプロエン酸誘導体、それらの製造法ならびにそれらを含有する抗てんかん剤または抗けいれん剤
KR20140107097A (ko) 1,5-디페닐-펜타-1,4-디엔-3-온 화합물
EP0154887B1 (en) New 2,5-diaryl tetrahydrothiophenes and analogs thereof as paf-antagonists
US4827011A (en) Antihypertensive phosphate derivatives
EP0087629A2 (en) Antiinflammatory and/or analgesic 2,3-Diaryl-5-halo thiophenes
FR2521992A1 (fr) Nouveaux composes de pyridine utiles comme medicaments
SU1005658A3 (ru) Способ получени производных гидантоина
EP1469842A2 (en) Bicyclic cb2 cannabinoid receptor ligands
JPS6112909B2 (fi)
AU2003209616A1 (en) Bicyclic CB2 cannabinoid receptor ligands
US4138407A (en) 2,4 Pyrrolidinediones
FI60711C (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara 5,5-dimetyl-8-(p-fluorfenylalkyl)-10-hydroxi-2-(2-propynyl)-1,2,3,4-tetrahydro-5h-bensopyrano (4,3-c) pyridiner
US3830852A (en) 2-benzylphenols
US5176908A (en) Method for the treatment of endotoxic shock in mammal
JPH053474B2 (fi)
USRE29196E (en) Alkylphenyl benzopyranopyridines
US4177283A (en) Aromatic prostaglandin analogues
US4201864A (en) Oxy-alkylamino acids and esters

Legal Events

Date Code Title Description
RH Patent void